Transitioning molecular imaging from a preclinical technique to a standard clinical tool could help detect the very earliest stages of disease, reports Tami Freeman Tools of the trade Left: this ...

Radiopharmaceutical therapy and molecular imaging—together known as Theranostics—are gaining significant traction worldwide. Even though Theranostics dates back to the early 1940s, a rapid expansion ...

The new imaging system, a noninvasive technology, analyzes the expression of a protein in pigmented lesions that correlates with tumor development. The system accurately discerned the difference ...

A new molecular imaging agent can accurately identify a crucial biomarker found among many different types of cancer. Precise visualization of the trophoblast cell surface antigen 2 (Trop2) biomarker ...

BERLIN & NAPLES, Fla.--(BUSINESS WIRE)--Bayer, a leading company in key areas of radiology and cardiology, and Attralus, Inc. (Attralus), a clinical stage biopharmaceutical company focused on ...

Approval marks a major milestone in reducing gadolinium exposure while maintaining diagnostic performance, aligning with clinical guidance to use the lowest effective dose MONTREAL, April 17, 2026 ...

The Case Comprehensive Cancer Center will host its next seminar series event Friday, Feb. 2, from noon to 1 p.m. in the Iris S. and Bert L. Wolstein Research Building auditorium. The event will ...

A novel molecular imaging agent targeting glypican-3 (GPC3) has demonstrated high sensitivity and specificity in detecting hepatocellular carcinoma (HCC), including tumors smaller than one centimeter, ...

FDA acceptance positions 18F-FET as a potential first-in-class US-approved amino acid PET agent for glioma characterization, addressing a major posttreatment imaging specificity gap.